Genefitletics

Sushant Kumar

This podcast is hosted by biotech entrepreneur Sushant Kumar, Founder & CEO of Genefitletics. Through this exclusive health podcast, he addresses the information asymmetry in the preventive health space. He is currently building Genefitletics, which is a direct-to-customer Biotech company- that studies & analyses activities of single & multicellular microorganisms living on & inside human body to provide precision health interventions in order to eradicate epidemic of chronic diseases, cancer & more.

  1. 4d ago

    PROGNORA: The AI Health Test That Predicts Disease Before It Starts

    Most of healthtech is racing to build sophisticated AI models on top of raw, surface-level sensory biomarkers and plasma data. But there is a fundamental flaw in this approach:The petabytes of legacy data collected by diagnostic labs and wearable companies over the past few decades fail to measure the root cause of almost every chronic disease, defects in mitochondrial function.Garbage in, garbage out. No matter how advanced your computational model is, if you aren't collecting the right raw material, the output won’t move the needle for clinical decision-making.Why Clinicians Skeptically Looked AwayHistorically, physicians understood the roles of the microbiome and mitochondria in disease pathogenesis, but traditional gut microbiome tests fell short. Identifying which bacteria were present left clinicians with the heavy lifting of figuring out: "What do we actually do with this information?" Without actionable insights, adoption stalled.Building the Deep-Tech Foundation at GenefitleticsWhen we founded Genefitletics 7 years ago, we took a radically different path:Focused strictly on collecting functional data: microbial gene expressions, secreted metabolites, and their direct cross-talk with mitochondria.Applied proprietary machine learning models to decode early risk signatures for cardiometabolic and oral diseases.Formulated targeted nutrition and biotherapeutic interventions that seamlessly integrate into standard-of-care protocols.When we launched our initial enterprise offering (ORAHYG PRO at ₹25,000/year), critics said the deep-tech strategy wouldn't survive.Seven years later, we’ve built a mammoth database of over 100 billion molecular data points calibrated specifically for the Indian population.Introducing PROGNORA: Mass-Market Precision HealthUsing this unprecedented dataset, we identified and quantified gene expressions and molecular pathways to create PROGNORA—a point-of-care, age- and gender-stratified prognostic AI model capable of detecting early systemic disease risks.We are making precision molecular health truly accessible.🎙️ On the latest episode of "The Living Algorithm", we break down the tech architecture, statistical tools, and clinical validation behind PROGNORA.Get Started with PROGNORALaunch Pricing: Now available at ₹5,000 (Special early-access pricing of ₹3,700 valid through October 31, 2026).For Clinicians & Dentists: We invite physicians, healthcare practitioners, and dental professionals to integrate PROGNORA into your diagnostic and treatment protocols.For Corporate Partners: Connect with us to bring cutting-edge preventative wellness solutions to your organization.Know more at: genefitletics.com/prognora

    PROGNORA: The AI Health Test That Predicts Disease Before It Starts

  2. Oct 15

    Prognora: Detect Disease Risk 7–10 Years Before Symptoms Appear

    Introducing Prognora: Detecting Disease Risk at the Cellular Level 7–10 Years Before Symptoms Appear 🧬✨Can cellular energetic abnormalities be detected before dysfunction appears? Can the cell’s bioelectric code be rewritten?After 7 years of deep research, 4 years of commercialization, and 8 validation studies, we at Genefitletics are thrilled to launch PRognora — our AI-driven prognostic model engineered specifically for disease risk profiling and disease-modifiable precision nutrition interventions.🔍 The Problem We SolvedDuring our direct-to-consumer phase processing over 100 billion molecular data points, we uncovered a critical truth: microbial stress drives increased energy expenditure, hypermetabolism, and allostatic overload at the cellular level.This effectively starves longevity pathways and triggers systemic conditions—such as Type 2 Diabetes, CVD, CKD, IBD, gum disease, and chronic inflammation—long before clinical symptoms ever manifest.🔬 How Prognora Changes the GameBy measuring the complex crosstalk between the oral & gut microbiome and mitochondrial energetics, PRognora:Decodes 50 + Active Pathways: Uses age- and gender-stratified AI models built on baseline biological pathway activity for the Indian adult population.Predicts Pre-Disease Risk: Identifies cellular dysfunction 7–10 years ahead of a standard clinical diagnosis.Delivers Point-of-Care Diagnostics in less than 5 Minutes: Translates hyper-personalized data into real-time prognostic biomarkers.Drives Targeted Interventions: Maps identified pathways to a proprietary therapeutic ontology for precision biotherapeutics and disease-modifiable nutrition.🌐 6 Key Health Domains CoveredImmune FunctionOral MicrobiomeGut MicrobiomeMetabolic HealthCognitive HealthNutrient Absorption Included is our real-time Red Flag Model, giving both consumers and practitioners visibility into how daily lifestyle choices impact molecular pathways and phenotypes.➕ Looking for total cellular optimization? PRognora seamlessly upgrades to ORAHYG PRO—our fully personalized cellular intelligence test analyzing oral-gut-mitochondrial crosstalk to reverse early metabolic disruption.The future of healthcare isn't reactive symptom management; it's proactive, pathway-level precision biotherapy.Know more at: www.genefitletics.com

    Prognora: Detect Disease Risk 7–10 Years Before Symptoms Appear

  3. Oct 12

    Blood Tests Can't Diagnose Disease Properly- Here's Why? | The Living Algorithm

    Early detection and companion therapeutics can dramatically improve survival rates, lower healthcare costs, and strengthen insurer economics.However, India’s current healthtech landscape is missing a critical distinction: Diagnosis vs. Prognosis.Most routine blood tests and wearables focus purely on diagnosis—detecting symptoms years after a disease has already manifested. Yet, many newly VC-funded healthtech and longevity startups promote a false narrative around "early detection" using these exact tools, ignoring that they only provide late-stage diagnostic markers, not prognostic foresight.When the foundation relies on late-stage markers, the outcome is usually just prescription drugs or generic nutrition advice—neither of which tackles the root cause.🔬 A Real-World Example: Thyroid DysfunctionOver 30% of Indians suffer from underactive thyroid function. The standard protocol checks TSH, Free T3, or T4 in the bloodstream. But this approach is deeply incomplete:Blood is just a transit system: Thyroid hormones function inside cells and mitochondria by binding to receptors. Blood tests can't confirm whether hormones are actually binding.Mitochondrial dysfunction blocks secretion: Hypothalamic signals require functional mitochondria in thyroid follicular cells to secrete T3 & T4. Inflammatory factors like TNF-Alpha or LPS disrupt this process.Conversion depends on gut health: Converting T4 to active T3 requires nutrients like Zinc and Selenium, whose absorption relies on a healthy gut microbiome.Cellular inflammation masks issues: Toxins, mold, or glyphosates can downregulate thyroid receptors. Even if your blood work looks "normal," thyroid hormones may fail to drive cellular ATP production.💡 The TakeawayDon't fall into the "early detection" trap built solely on routine blood work. Traditional blood panels are designed for disease management and drug prescription—not for uncovering early molecular drivers of chronic illness.🎧 Catch Episode 10 of "The Living Algorithm" where we dive deep into the flaws of blood-test-centric approaches to chronic disease.

    Blood Tests Can't Diagnose Disease Properly- Here's Why? | The Living Algorithm

  4. Sep 17

    The Hidden Risks of Perimenopause Blood Sugar, Heart Health & Your Mouth | The Living Algorithm Ep-9

    Perimenopause and menopause bring significant estrogen fluctuations, creating a cascading impact on systemic biological health. Yet, the precise molecular mechanisms driving this shift have largely remained unaddressed—until now.Low estrogen levels directly alter the oral and gut microbiomes, triggering a cascade of microbial dysbiosis, harmful metabolites, and endotoxins like Lipopolysaccharides (LPS). This systemic shift dramatically increases the risk for conditions ranging from Type 2 diabetes, cardiovascular disease, obesity, and fatty liver to anxiety, depression, and sexual dysfunction.How do we regulate estrogen pathways and blunt these pro-inflammatory cascades? What role does cellular energy and mitochondrial health play in mitigating these risks?In Episode 8 of "The Living Algorithm," we dive deep into:Mitochondrial Crosstalk: The critical function of ovarian and adipocyte mitochondria in regulating estrogen balance.The Estrogen-Gut Axis: How declining estrogen drives gut microbial dysbiosis, lowers beneficial short-chain fatty acids (SCFAs), and elevates systemic LPS endotoxins.Intimate & Oral Health: The direct link between low estrogen, oral dysbiosis, SIBO, vaginal microbial imbalances, yeast infections, and bacterial vaginosis.Metabolic & Mental Health: How gut-derived endotoxins fuel chronic inflammation, driving cardiometabolic diseases alongside mood disturbances like anxiety and depression.We break down the underlying biological mechanisms connecting hormonal transitions to multi-system disease risks.🎧 Catch the full episode on "The Living Algorithm" to explore the science behind female biology, cellular health, and preventative care.

    The Hidden Risks of Perimenopause Blood Sugar, Heart Health & Your Mouth | The Living Algorithm Ep-9

  5. Sep 10

    Glowing Danger: Does LED Blue Light Cause Cancer? | The Living Algorithm Ep-8

    More than 90% of Indians are now at elevated risk of cancer, especially hormone-related cancers like breast and prostate cancer.While poor diet, obesity, and metabolic disease get most of the attention, one critical and largely ignored factor is silently accelerating abnormal cell growth: artificial blue light from LEDs.Sunlight delivers a complete spectrum ultraviolet, blue, green, yellow, red, and infrared that our cells are designed to receive. Specialized light-sensitive molecules (chromophores) absorb these photons and trigger powerful biological signals:UV light drives Vitamin D synthesisNatural blue light energizes immune cellsGreen & yellow light support circadian rhythm, collagen, and tissue repairRed light supports visionInfrared light supercharges mitochondria, boosts natural melatonin, reduces inflammation, and activates cellular repair & restorationModern life has largely cut us off from this free, life-supporting energy. Instead, after sunset we bathe in intense artificial blue light from LEDs, screens, and indoor lighting.This blue light:Suppresses melatonin production, tricking our cells into thinking it’s still daytime, shutting down overnight repair and weakening defenses against abnormal cell growth.Disrupts cytochrome C oxidase in mitochondria, increasing reactive oxygen species, lowering ATP, and pushing cells into a depolarized, cancer-prone state.Opens calcium channels, allowing excess calcium into cellsElevates estrogen levels by lowering melatonin, which can trigger mast cell activation and raise autoimmune riskIn Episode 7 of The Living Algorithm, we break down exactly how chronic exposure to artificial blue light and LED lighting is disrupting your circadian biology and elevating your cancer risk — and what you can do about it.This is one of the most important (and under-discussed) health conversations of our time.Worth every minute of your attention.🎧 Listen / Watch now:#BlueLightCancer #LEDLightDanger #MelatoninKiller #CircadianDisruption #BreastCancerAwareness #ProstateCancer #HormonalCancer #BlueLightToxicity #NaturalLightHealing #TheLivingAlgorithm #MitochondrialHealth #CancerPrevention #IndiaHealth #ScreenTimeDanger #NightLightRisk #ArtificialLightHazard #CellularRepair #HealthyCircadianRhythm

    Glowing Danger: Does LED Blue Light Cause Cancer? | The Living Algorithm Ep-8

  6. Sep 2

    Why ‘Normal’ Blood Work Misses Early Diabetes and Heart Risk? | The Living Algorithm Ep-7

    Routine blood tests have been the gold standard for medical investigations for decades. Today, a new wave of shallow tech and copycat digital health platforms are combining these standard blood panels with wearable data, framing it as the ultimate solution for preventive health.Yet, actual clinical outcomes haven't improved—they’ve worsened:Diabetes: Over 250 million Indians live with diabetes, and nearly 150 million remain undiagnosed because standard blood panels still flag them as “normal.”Cardiovascular Disease: Heart disease remains the world's leading killer, while conventional care relies almost entirely on tracking basic cholesterol levels.Kidney Health: Renal dysfunction is routinely caught at advanced stages, relying on reactive eGFR metrics that often lead straight to dialysis.The core issue? We are obsessed with measuring the post-mortem of biochemical processes—spotting abnormal blood biomarkers and immediately masking them with drugs, generic supplements, or cookie-cutter diet plans.Standard blood panels fail to:Identify the molecular drivers causing those abnormal blood values.Detect early inflammatory cascades, cytokine signaling, or cellular stress long before plasma levels shift.Disease manifests at a cellular level decades before it shows up on a blood test, MRI, CT, or DEXA scan.Relying solely on blood work and wearable gadgets without decoding cellular dysfunction will never fix root-cause health. Take Type 2 Diabetes: the system hyper-focuses on suppressing blood glucose and HbA1c, completely ignoring the cellular drivers of hyperinsulinemia. A glucose spike is often just a symptom of underlying inflammation; tracking it via standard labs or continuous glucose monitors (CGMs) won't reverse the condition.In Episode 7 of The Living Algorithm, we dive deep into why basing your health strategy strictly on traditional blood work and basic wearables fails to prevent cardiometabolic disease.

    Why ‘Normal’ Blood Work Misses Early Diabetes and Heart Risk? | The Living Algorithm Ep-7

  7. Aug 27

    The Fungal Theory of Cancer: Cell Suppression Explained | The Living Algorithm Ep-6

    The dominant somatic mutation theory only explains 2 out of 10 hallmarks of cancer. So why is the conventional oncology model still almost exclusively focused on sequencing DNA and targeting downstream genetic mutations?Otto Warburg showed decades ago that cancer is fundamentally driven by mitochondrial dysfunction. When cellular energy production breaks down, cells revert to an ancient, oxygen-deprived fermentation model. This inefficient energy output floods the environment with lactic acid, shielding cancer cells and fueling further growth.Despite this, mainstream protocols continue to treat genetic mutations—which are downstream epiphenomena—with toxic drugs. The result? Over 2,500 people in India die of cancer every single day.To solve cancer, we must ask what damages the mitochondria in the first place.Enter the Cell Suppression Theory. Driven by pathogen virulence and toxic bi-products, this model explains how mitochondrial damage occurs—and accounts for all 10 hallmarks of cancer.In Episode 6 of The Living Algorithm, we dive deep into:Pathogen Dynamics: The direct role of fungal, bacterial, and viral pathogens in cancer onset.The Vulnerability Loop: How chronic inflammation and the Cell Danger Response enable fungal invasion.Metabolic Defense: How the shift to lactic acid production actively feeds fungal growth and damages cell membranes.Clinical Protocol Shifts: Why oncologists must incorporate microbiome health, mitochondrial integrity, and metabolic therapy into standard care.If you are ready to look beyond outdated paradigms, this 25-minute conversation is essential viewing.#Cancer #Fungi #FungalTheoryOfCancer #CellSuppressionTheory #Mycobiome #CancerResearch #AlternativeHealth #HealthSecrets #DidYouKnow #Science

    The Fungal Theory of Cancer: Cell Suppression Explained | The Living Algorithm Ep-6

  8. Aug 20

    Can the Gut Microbiome Rescue Failed Immunotherapy | The Living Algorithm Ep-5

    The 5-year therapeutic success rate for cancer in India sits below 11%, with over 100 lives lost to the disease every single hour. While current standard-of-care treatments like chemotherapy and immunotherapy offer breakthroughs for a select subset of patients, they fall short for the vast majority. Why do Immune Checkpoint Inhibitors (ICIs) fail so many? A primary culprit is T-cell exhaustion coupled with mitochondrial dysfunction. Standard immunotherapies struggle when the tumor microenvironment actively disables the host immune response through: Nutrient Competition & Amino Acid Reprogramming: Cancer cells hijack methionine and tryptophan metabolism. By elevating S-adenosylmethionine (SAM), tumor cells alter gene expression to downregulate AMPK, upregulate PD-1 expression, and force CD4+ T-cell exhaustion. Mitochondrial Impairment: Nutrient depletion and toxic fermentation byproducts collapse mitochondrial membrane potential, deplete ATP production, and suppress PGC-1α—disarming the T-cell’s mechanical ability to destroy tumor cells. Persistent Antigen & Metabolite Exposure: Ongoing stress signals suppress T-cell proliferation and strip away effector functions. Overcoming immunotherapy resistance requires looking beyond cell surface receptors to the biochemical signals driving the microenvironment—where the gut microbiome plays a pivotal role. Microbial-derived metabolites and postbiotics hold the key to restoring mitochondrial energetics, reversing T-cell dysfunction, and enhancing PD-1 therapy outcomes. In Episode 5 of The Living Algorithm, we unpack: The root mechanisms behind immunotherapy non-responsiveness The biophysical drivers of T-cell exhaustion How mitochondrial bioenergetics dictate CAR-T and ICI efficacy How targeted gut microbial metabolites can restore T-cell cytotoxicity Listen to the full discussion here:  #CancerResearch #Immunotherapy #Oncology #GutMicrobiome #Immunometabolism #CellularHealth #Biotechnology #PrecisionMedicine #TheLivingAlgorithm #TCellExhaustion #Mitochondria #Metabolomics

    Can the Gut Microbiome Rescue Failed Immunotherapy | The Living Algorithm Ep-5
See All (120)

About

This podcast is hosted by biotech entrepreneur Sushant Kumar, Founder & CEO of Genefitletics. Through this exclusive health podcast, he addresses the information asymmetry in the preventive health space. He is currently building Genefitletics, which is a direct-to-customer Biotech company- that studies & analyses activities of single & multicellular microorganisms living on & inside human body to provide precision health interventions in order to eradicate epidemic of chronic diseases, cancer & more.

Information

  • Creator
    Sushant Kumar
  • Years Active
    2020 - 2026
  • Episodes
    120
  • Rating
    Explicit
  • Copyright
    © Sushant Kumar
  • Show Website
    Genefitletics